Refractory or Relapsed Osteosarcoma Clinical Trial
Official title:
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
The purpose of this study is to determine the Everolimus aim response in children and
adolescents with refractory or relapsed osteosarcoma.
The aim response is defined as complete or partial response (according to RECIST criteria)
for at least 4 weeks, or stable disease for at least 12 weeks.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment